{"denomUnitsSelected":"Participants","description":"Plasma trough levels will be obtained weekly through the first cycle to provide a steady-state assessment. Steady-state plasma concentrations will be calculated for each patient. Exploratory correlative studies between veliparib exposure (plasma and bone marrow) with pharmacodynamic (biological endpoints, toxicity and efficacy) will be analyzed using nonparametric statistics. Significance for comparisons will be at the p \\< 0.05 level.","reportingStatus":"NOT_POSTED","timeFrame":"Pre-treatment, day 1, day 8, day 14, day 15, and day 22 (approximately 24 hours post last dose)","title":"Pharmacokinetic Sampling Studies Measured Using a Validated Liquid Chromatography/Tandem Mass Spectrometric Method in Plasma and Bone Marrow","type":"SECONDARY"}